{
  "title": "Vitamin D3 in Systemic Lupus Erythematosus",
  "identifier": {
    "identifier": "http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY474",
    "identifierSource": "http://www.immport.org"
  },
  "producedBy": {  "name": "Vitamin D3 in Systemic Lupus Erythematosus",
  "performedBy": [
    {
      "firstName": "Cynthia",
      "lastName": "Aranow",
      "email": "caranow@nshs.edu",
      "affiliations": [
          {
             "name": "Feinstein Institute for Medical Research NS-LIJ Health System"
          }
      ],
      "roles": [
          {
             "value": "Principal Investigator"
          }
      ]
    }
  ],
  "studyGroups": [
        {
          "name": "4000 IU Vitamin D",
          "size": 19
        },
        {
          "name": "2000 IU Vitamin D",
          "size": 19
        },
        {
          "name": "Placebo",
          "size": 19
        }
  ],
  
  "usesReagent": [
        {
          "name": "SuperScript III RNase H  Reverse Transcriptase"
        },
        {
          "name": "dNTP Mix"
        },
        {
          "name": "Oligo(dT)12-18 Primer"
        },
        {
          "name": "Ribonuclease H"
        },
        {
          "name": "RNaseOUT Recombinant RNase Inhibitor"
        },
        {
          "name": "2X iQ SYBR Green Supermix"
        }
  ],
  
  "selectionCriteria": [
        {
          "category": "Inclusion",
          "values": [
              "Subject has provided written informed consent."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Subject is >= 18 years of age."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Meets at least 4 of 11 modified American College of Rheumatology (ACR) 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus as updated in 1997."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Serum 25-OH vitamin D level less than or equal to 20 ng/mL."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Stable disease at Screening, defined as a modified SELENA SLEDAI <= 4."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Interferon signature present. Determination of the IFN alpha signature will be assessed by measuring expression levels of 3 IFN alpha responsive genes, Mx1, Ifit1, and Ifi44 using RT-PCR in mRNA extracted from PBMCs. The mean and standard deviation for normal controls is determined for each gene. The signature is present if one of the 3 genes is expressed at a level greater than or equal to 4 standard deviations above the mean of normal controls or if 2 of the 3 genes are expressed more than 2 standard deviations above the mean of normal controls."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Positive anti-dsDNA antibody at the time of screening."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "If on corticosteroids, the dose must be < 20mg per day and stable for the 4 weeks prior to screening and at baseline."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "If on immunosuppressive or immunomodulatory medication such as azathioprine, methotrexate, leflunomide, mycophenolate, or hydroxychloroquine, the dose must be stable for the 3 months prior to screening and baseline, and expected to remain stable over the course of the study."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "If taking a multivitamin or a vitamin D supplement, the dose of vitamin D must be less than or equal to 800 IU daily and stable for the 3 months prior to screening and at baseline."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "Males and females with reproductive potential must agree to practice effective measures of birth control."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "History of receiving any multivitamin, supplement, or drug containing more than 800 IU daily of vitamin D within the last 3 months."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Unwillingness to stop using drugs or substances that interfere with or may interfere with fat absorption (e.g., Orlistat)."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Hypercalcemia (serum calcium > 10.4 mg/dl) at screening."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Hypercalciuria (urinary calcium/creatinine ratio = 0.8) at screening."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "History of hyperparathyroidism."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "History of renal stones."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "History of cancer, except cervical carcinoma in situ and resected basal and squamous cell carcinomas of the skin."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Known history of chronic viral infections, including HIV, Hepatitis B, and Hepatitis C."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Known active tuberculosis."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Any BILAG A or B manifestation with the exception of a BILAG B mucocutaneous manifestation."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "ALT or AST = 2x upper limit of normal."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Dialysis or serum creatinine > 1.5 mg/dl."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Expectation by the investigator to increase corticosteroid or immunosuppressive, or immunomodulatory medication dose at screening, baseline, or over the course of the study."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Current treatment with cyclophosphamide or a biologic."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Treatment with cyclophosphamide within 3 months prior to screening."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Treatment with rituximab within the 12 months prior to screening."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Other Investigational drug and/or treatment during the 4 weeks or seven half-lives of the other investigational drug prior to the start of study drug dosing (Day 0), whichever is the greater length of time."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Drug or alcohol abuse within 6 months prior to randomization."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Pregnancy or lactation."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Treatment with digoxin."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Treatment with teriparatide (Forteo)."
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "Any condition that, in the opinion of the Investigator, would jeopardize the subject?s safety following exposure to the study drug."
          ]
        }
  ],
  
  "types": [
      {
          "value": "Interventional"
      }
  ]
  },
  "creators": [
    {
      "firstName": "Cynthia",
      "lastName": "Aranow",
      "email": "caranow@nshs.edu",
      "affiliations": [
          {
             "name": "Feinstein Institute for Medical Research NS-LIJ Health System"
          }
      ],
      "roles": [
          {
             "value": "Principal Investigator"
          }
      ]
    },
    {
      "name": "EFFECT OF VITAMIN D3 ON THE IFNA SIGNATURE IN PATIENTS WITH LUPUS (ALE02)",
      "extraProperties": [
        {
          "category": "Catgory",
          "values": [
            {
              "value": "DAIT"
            }
          ]
        },
        {
          "category": "External Id",
          "values": [
            {
              "value": "5M01RR018535-08"
            }
          ]
        },
        {
          "category": "Description",
          "values": [
            {
              "value": "This multi-center double-blind placebo controlled trial will investigate the effect of vitamin D supplementation on the interferon signature in patients with systemic lupus erythrematosus. Vitamin D deficient patients with spell out who possess the interferon signature will be randomized to receive 0, 2000 or 4000 IU/daily of cholecalciferol (vitamin D3) for 12 weeks. Potential clinical effects as well as safety will be assessed and monitored "
            }
          ]
        }
      ]
    }
  ],
  
  "primaryPublications": [
    {
      "identifier":
        {
          "identifier": "25777546",
          "identifierSource": "pubmed"
        },
      "authorsList": "Aranow C(1), Kamen DL(2), Dall'Era M(3), Massarotti EM(4), Mackay MC(1), Koumpouras F(5), Coca A(6), Chatham WW(7), Clowse ME(8), Criscione-Schreiber LG(8), Callahan S(9), Goldmuntz EA(9), Keyes-Elstein L(10), Oswald M(1), Gregersen PK(1), Diamond B(1).",
      "title": "Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus.",
      "publicationVenue": "Arthritis Rheumatol.",
      "dates": [
        {
          "date": "2015",
          "type": { "value": "publication year" }
        }
      ]
    }
  ],
  "types": [
      {
        "value": "Clinical Trial"
      },
      {
        "value": "Interventional"
      },
      {
        "value": "Autoimmune"
      }
  ],
  "dates": [
      {
          "date": "2008-11-01",
          "type": {
              "value": "actual_start_date"
          }
      },
      {
          "date": "2015-09-18",
          "type": {
              "value": "final_public_release_date"
          }
      }
  ],
  "availability": "Available for download after registration with ImmPort",
  "refinement": "Curated",
  "dimensions": [{
        "name": {
            "value": "Molecular Quantification"
        },
        "description": "None",
        "types": [
            {
               "value": "Q-PCR"
            }
        ]
      },{
        "name": {
            "value": "Hematology test"
        }
      },{
        "name": {
            "value": "Comprehensive Metabolic Panel"
        }
      },{
        "name": {
            "value": "Immunology laboratory test"
        }
      },{
        "name": {
            "value": "Vitamin measurement"
        }
      },{
        "name": {
            "value": "Hormone measurement"
        }
      }
      
  ],
  "isAbout": [
        {
          "name": "IFNa stimulation"
        }
  ],
  "distributions": [
      {
          "identifier": {
              "identifier": "SDY474",
              "identifierSource": "ImmPort"
          },
          "title": "Vitamin D3 in Systemic Lupus Erythematosus",
          "access": {
              "landingPage": "http://www.immport.org",
              "accessURL": "http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY474",
              "types": [
                  {
                      "value": "Download tab separated files"
                  },
                  {
                      "value": "Download MySQL files and schema"
                  }
              ],
              "authorizations": [
                {
                    "value": "Registraton with ImmPort required"
                }
              ]
          },
          "storedIn": {
              "name": "ImmPort",
              "types": [
                {
                  "value": "primary repository"
                }
              ]
         },
         "licenses": [
           {
             "name": "ImmPort User Agreement",
             "version": "1.0",
             "extraProperties": [
               {
                 "category": "Link to User Agreement",
                 "values": [
                   {
                     "value": "http://www.immport.org/agreement"
                   }
                 ]
               }
             ]
           }
         ]
      }
  ],
  "acknowledges": [
    {
      "identifier": {
        "identifier": ""
      },
      "name": "EFFECT OF VITAMIN D3 ON THE IFNA SIGNATURE IN PATIENTS WITH LUPUS (ALE02)",
      "extraProperties": [
        {
          "category": "Link",
          "values": [
            {
              "value": "http://projectreporter.nih.gov/project_info_description.cfm?aid=6880173"
            }
          ]
        }
      ]}
  ],
  "licenses": [
    {
      "name": "ImmPort User Agreement",
      "version": "1.0",
      "extraProperties": [
        {
          "category": "Link to User Agreement",
          "values": [
            {
              "value": "http://www.immport.org/agreement"
            }
          ]
        }
      ]
    }
  ],
  "description": "This is a double-blind, multi-center, placebo controlled, Phase II study designed to assess biologic effects of 12 weeks of vitamin D3 supplementation on patients with well-controlled stable systemic lupus erythematosus who have low serum levels of 25-OH vitamin D and an IFN alpha signature."
}
